Abstract: FR-PO0837
Association of Serum and Urinary Fibrinogen with Prognosis and Disease Severity in Patients with IgAN
Session Information
- Glomerular Diseases: Practice and New Concepts Shaping Modern Care
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Ueda, Masataka, Showa Daigaku, Shinagawa, Tokyo, Japan
- Suzuki, Taihei, Showa Daigaku, Shinagawa, Tokyo, Japan
- Kobayashi, Kazuki, Showa Daigaku, Shinagawa, Tokyo, Japan
- Tamura, Shiho, Showa Daigaku, Shinagawa, Tokyo, Japan
- Kajio, Yuki, Showa Daigaku, Shinagawa, Tokyo, Japan
- Kanazawa, Nobuhiro, Showa Daigaku, Shinagawa, Tokyo, Japan
- Honda, Hirokazu, Showa Daigaku, Shinagawa, Tokyo, Japan
Background
IgA nephropathy (IgAN) is an inflammatory glomerular disease, and characterized by immune complex deposition in mesangial area, leading to progressive renal dysfunction. Although fibrinogen is a biomarker associated with inflammation, the clinicopathological roles of fibrinogen in patients with IgAN has not been elucidated. We investigated whether serum and urinary fibrinogen could be predictors of IgAN prognosis.
Methods
The patients diagnosed with IgAN based on the findings of kidney biopsy at Showa Medical University Hospital between January 2014 and September 2024 were enrolled to this study (n = 126). eGFR decline, remission, and relapse were included as clinical outcomes. We also evaluated the correlation between the titer of fibrinogen and MEST-C score. Statistical analysis were performed using Spearman’s rank correlation coefficient, and the Mann-Whitney U test was used for group comparisons. Univariate Cox proportional hazards analysis and Kaplan-Meier analysis with the Log-rank test were used for survival analysis. A P value <0.05 was considered statistically significant.
Results
Serum fibrinogen levels were significantly higher in patients who relapsed or failed to achieve remission than in those who achieved remission without relapse (384.0 vs 296.5 mg/dL, P = 0.0163). Urinary fibrinogen to creatinine ratio (uF/C) was significantly higher in patients who reached the endpoints of ≥25% or ≥50% decline in eGFR than in those who did not reach. Cox proportional hazards analysis demonstrated that the high uF/C group was associated with an increased risk of a ≥25% decline in eGFR (HR, 5.62; 95% CI, 1.48–36.60; P = 0.0260). Kaplan-Meier analysis further demonstrated that the high uF/C group had a significantly higher cumulative incidence of a ≥ 25% decline in eGFR than the low uF/C group (Log-rank, P=0.0120). Histologically, uF/C was significantly higher in patients with S, T, and C lesions, whereas serum fibrinogen levels were significantly higher in patients with T and C lesions.
Conclusion
In the current study, serum fibrinogen and the uF/C were associated with clinical outcomes and histological severity in patients with IgAN. These findings suggest that fibrinogen may serve as potential biomarkers for assessing disease activity and progression in IgAN. Further clinical investigation are required to more detailed pathophysiological roles of fibrinogen in IgAN.